STOCK TITAN

GLOBUS MEDICAL INC - GMED STOCK NEWS

Welcome to our dedicated page for GLOBUS MEDICAL news (Ticker: GMED), a resource for investors and traders seeking the latest updates and insights on GLOBUS MEDICAL stock.

Globus Medical Inc. (NYSE: GMED) is a leading manufacturer of musculoskeletal implants and a pioneer in advancing spinal surgery through technological innovations. Founded in 2003, the company is renowned for its commitment to improving the quality of life for patients suffering from spinal disorders. With a focus on superior engineering and technology, Globus Medical offers a comprehensive suite of spinal products designed to facilitate pain-free, active living.

Globus Medical's product portfolio is divided into two main categories:

  • Musculoskeletal Solutions: This segment includes an array of medical devices and instruments primarily used for spinal and orthopedic procedures. These products are the primary revenue drivers for the company, with a significant portion of sales generated within the United States.
  • Enabling Technologies: This category features advanced computer systems developed to enhance surgical capabilities, providing surgeons with innovative tools to improve patient outcomes.

The company's dedication to innovation has made it the fastest-growing entity in the history of orthopedics. Recent achievements highlight this growth trajectory. Globus Medical announced an increase in its full-year fiscal 2023 revenue guidance to $1.55 billion, up from $1.125 billion, with non-GAAP fully diluted earnings per share reaffirmed at $2.30. Looking ahead, the company has updated its full-year 2024 revenue guidance to a range of $2.460 billion to $2.485 billion and non-GAAP fully diluted earnings per share between $2.75 and $2.85.

Globus Medical continues to foster strong partnerships and engage in cutting-edge projects aimed at expanding its market presence and technological capabilities. The company's headquarters are located in Audubon, PA, and it remains actively involved in the medical community through participation in teleconferences, investor calls, and industry events.

For more information about their latest products, financial performance, and upcoming events, you can visit the Globus Medical website at www.globusmedical.com.

Rhea-AI Summary
Globus Medical, Inc. (NYSE:GMED) will release its first-quarter financial results on May 7, 2024, followed by a conference call to discuss its performance with investors. The release will be available on the company's website, and participants can join the call via webcast or telephone.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.14%
Tags
-
Rhea-AI Summary
Globus Medical, Inc. (NYSE: GMED) reported strong financial results for Q4 2023 and full year 2023, with record worldwide net sales. The merger with NuVasive has been successful, driving growth and enhancing customer service. The company remains focused on innovation, product launches, and merger integration. Despite a decrease in GAAP net income for Q4 2023 due to acquisition costs, non-GAAP net income increased. The company reaffirmed its 2024 revenue guidance range and earnings per share expectations.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.55%
Tags
-
Rhea-AI Summary
Globus Medical, Inc. (GMED) will release its financial results for Q4 and full year 2023 on February 20, 2024. The company will host a teleconference to discuss its performance with investors. Participants can join via webcast or telephone.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.15%
Tags
Rhea-AI Summary
Globus Medical, Inc. (NYSE: GMED) has promoted Keith Pfeil to the role of chief operating officer (COO) and chief financial officer (CFO) to drive the company's strategic roadmap through business and operational planning and financial performance management. Pfeil will oversee all day-to-day operational activities and financial activities, representing the organization to external stakeholders. The company expects to announce its fourth quarter and full year 2023 financial results on February 20, 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.44%
Tags
none
-
Rhea-AI Summary
Globus Medical, Inc. (NYSE: GMED) anticipates fourth quarter 2023 sales of approximately $615.5 million, an increase of 124.2 percent over the fourth quarter 2022. Full year 2023 sales are expected to be approximately $1.567 billion, an increase of 53.2 percent over the prior year. The company is well positioned for future growth drivers in the broader musculoskeletal market and has established its full year 2024 revenue guidance range of $2.450 billion to $2.475 billion.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.25%
Tags
-
Rhea-AI Summary
NYSE: GMED - Globus Medical Announces Strong Q3 2023 Financial Results and Raises 2023 Revenue Guidance to $1.55 Billion
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.69%
Tags
Rhea-AI Summary
Globus Medical, Inc. will announce its financial results for Q3 2023 on November 7. A teleconference will be held to discuss performance with the investment community.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.34%
Tags
-
Rhea-AI Summary
Globus Medical presents positive five-year outcomes from the NuVasive Simplify Cervical Disc study, demonstrating long-term clinical success and superiority over ACDF procedural outcomes.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.24%
Tags
none
-
Rhea-AI Summary
Globus Medical celebrates twenty years of the NuVasive XLIF procedure at SMISS '23 Annual Forum.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.38%
Tags
none
Rhea-AI Summary
Globus Medical continues partnership with EUROSPINE and will attend EUROSPINE 2023. They will showcase their musculoskeletal solutions at various conferences in Q4 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.93%
Tags
none

FAQ

What is the current stock price of GLOBUS MEDICAL (GMED)?

The current stock price of GLOBUS MEDICAL (GMED) is $82.71 as of January 1, 2025.

What is the market cap of GLOBUS MEDICAL (GMED)?

The market cap of GLOBUS MEDICAL (GMED) is approximately 11.3B.

What does Globus Medical Inc. specialize in?

Globus Medical Inc. specializes in developing and manufacturing musculoskeletal implants and advanced computer systems for spinal and orthopedic procedures.

When was Globus Medical Inc. founded?

Globus Medical Inc. was founded in 2003.

What are the main product categories of Globus Medical?

Globus Medical's products are categorized into Musculoskeletal Solutions and Enabling Technologies.

Where is Globus Medical Inc. headquartered?

Globus Medical Inc. is headquartered in Audubon, Pennsylvania.

How can I access the latest financial results of Globus Medical?

You can access the latest financial results on the Investors page of the Globus Medical website at www.investors.globusmedical.com.

What is the company's revenue guidance for the fiscal year 2024?

Globus Medical has provided a revenue guidance range of $2.460 billion to $2.485 billion for the fiscal year 2024.

How does Globus Medical contribute to spinal surgery advancements?

Globus Medical utilizes superior engineering and technology to develop innovative spinal products that improve surgical outcomes and patient quality of life.

What percentage of Globus Medical's revenue comes from the United States?

More than half of Globus Medical's revenue is generated in the United States.

How can investors participate in Globus Medical’s teleconference calls?

Investors can participate in teleconference calls by registering in advance via the link provided on the Investors page of the Globus Medical website.

Where can I find more information about Globus Medical's products and services?

More information about Globus Medical's products and services can be found on their official website at www.globusmedical.com.
GLOBUS MEDICAL INC

NYSE:GMED

GMED Rankings

GMED Stock Data

11.26B
135.30M
0.62%
81.91%
1.79%
Medical Devices
Surgical & Medical Instruments & Apparatus
Link
United States of America
AUDUBON